ALPN insider transaction filings

ALPINE IMMUNE SCIENCES, INC. — 13 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2024-05-20. Screen ALPN transaction legs live →

Insider transaction summary — last 90 days

No Form 4 filings for ALPN between 2026-06-11 and 2026-09-09. The table below lists the most recent filings on record.

Recent Form 4 filings — ALPINE IMMUNE SCIENCES, INC.

FiledFormInsiderReported transactionsSource
2024-05-204Hernday Natasha — DirectorDisposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 17,500 (derivative)EDGAR
2024-05-204Drappa Jorn — DirectorDisposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 17,500 (derivative)EDGAR
2024-05-204PENG STANFORD L — See RemarksDisposition to issuer (D): 296,163 · Disposition to issuer (D): 48,000 · Disposition to issuer (D): 42,407 (derivative) · Disposition to issuer (D): 236,623 (derivative) · Disposition to issuer (D): 71,874 (derivative) · Disposition to issuer (D): 50,000 (derivative) · +5 moreEDGAR
2024-05-204FUHS ULRICH MARTIN — Chief Accounting OfficerDisposition to issuer (D): 22,820 · Disposition to issuer (D): 7,300 · Disposition to issuer (D): 52,180 (derivative) · Disposition to issuer (D): 28,700 (derivative) · Disposition to issuer (D): 14,600 (derivative)EDGAR
2024-05-204DURAND REMY — Chief Business OfficerDisposition to issuer (D): 102,192 · Disposition to issuer (D): 31,200 · Disposition to issuer (D): 2,635 (derivative) · Disposition to issuer (D): 26,922 (derivative) · Disposition to issuer (D): 70,155 (derivative) · Disposition to issuer (D): 112,500 (derivative) · +2 moreEDGAR
2024-05-204Peetz Christopher — DirectorDisposition to issuer (D): 1,900 · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 10,000 (derivative) · +2 moreEDGAR
2024-05-204Rickey James Paul — See RemarksDisposition to issuer (D): 26,761 · Disposition to issuer (D): 31,200 · Disposition to issuer (D): 836 (derivative) · Disposition to issuer (D): 137 (derivative) · Disposition to issuer (D): 143 (derivative) · Disposition to issuer (D): 1,214 (derivative) · +4 moreEDGAR
2024-05-204Cui Xiangmin — Director, 10% owner
Decheng Capital China Life Sciences USD Fund III, L.P. — 10% owner
Decheng Capital Management III (Cayman), LLC — 10% owner
Decheng Capital Global Healthcare Fund (Master), LP — 10% owner
Decheng Capital Global Healthcare GP, LLC — 10% owner
Code (U): 6,582,380 · Code (U): 1,735,544 · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 10,000 (derivative) · +2 moreEDGAR
2024-05-204Thompson Peter A. — DirectorCode (U): 2,416,181 · Code (U): 264,315 · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 7,650 (derivative) · +3 moreEDGAR
2024-05-204Topper James N — DirectorCode (U): 2,829,347 · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 10,000 (derivative) · +2 moreEDGAR
2024-05-204GOLD MITCHELL — Executive Chairman and CEO, DirectorCode (U): 2,627,157 · Disposition to issuer (D): 13,245 · Disposition to issuer (D): 96,000 · Disposition to issuer (D): 70,000 (derivative) · Disposition to issuer (D): 247,951 (derivative) · Disposition to issuer (D): 208,916 (derivative) · +6 moreEDGAR
2024-05-204CONWAY ROBERT E — DirectorDisposition to issuer (D): 50,000 · Disposition to issuer (D): 2,868 (derivative) · Disposition to issuer (D): 3,075 (derivative) · Disposition to issuer (D): 1,912 (derivative) · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 7,650 (derivative) · +5 moreEDGAR
2024-05-204ORBIMED ADVISORS LLC — Director
OrbiMed Capital GP VI LLC — Director
OrbiMed Genesis GP LLC — Director
Code (U): 2,416,181 · Code (U): 264,315EDGAR

Recent 8-K events — ALPINE IMMUNE SCIENCES, INC.

FiledFormItems reportedSource
2024-05-208-K1.02 — Termination of a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
3.03 — Material Modification to Rights of Security Holders
5.01 — Changes in Control of Registrant
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=ALPN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →